Tropisetron

Tropisetron was developed for nausea and vomiting, not cognition. As a 5-HT3 antagonist it was effective against acute chemotherapy-induced emesis, and a six-day randomised trial found 5 mg better than 2 mg for acute nausea and vomiting, at the cost of more headache [6]. Reviews place it alongside ondansetron and granisetron; combining it with dexamethasone worked better than tropisetron alone in older chemotherapy trials [1].

The cognitive interest comes from a second action. Tropisetron is a partial agonist at the α7 nicotinic receptor, a receptor implicated in attention and in the P50 auditory-gating deficit seen in schizophrenia [2]. In an eight-week trial of 40 patients taking risperidone, 10 mg daily improved P50 gating in nonsmokers and one sustained-attention task, without changing schizophrenia symptoms [3].

A ten-day dose-ranging trial in 40 nonsmoking patients reported better overall cognition at 5, 10 and 20 mg and correlations between cognitive and P50 changes [4]. A separate one-day study, again with 40 nonsmokers on risperidone, found improvements on selected RBANS and P50 measures, but the dose pattern was not monotonic: total RBANS improved at 5 and 20 mg, immediate memory at 10 mg, and P50 ratio at 5 and 10 mg [5]. That irregular pattern, tiny samples and repeated testing make the results hypothesis-generating.

5-HT3 antagonism explains the antiemetic. 5-HT3 is an ion-channel serotonin receptor in peripheral vagal pathways and central emetic circuitry. Blocking it prevents much of the acute nausea and vomiting triggered by chemotherapy; delayed emesis responds less completely because other transmitters contribute [1].

α7 partial agonism explains the nootropic interest. In frog oocytes expressing human receptors, tropisetron activated α7 nicotinic receptors as a selective partial agonist. Dissecting the molecule showed that its charged tropane nitrogen was sufficient for weak activation, while the indole-containing whole molecule supplied potency and subtype selectivity [2]. The same experiment found blockade of α3β4 but not α4β2 nicotinic receptors [2].

In a mouse model built with repeated phencyclidine exposure, two weeks of tropisetron improved recognition-memory deficits, and an α7 antagonist blocked that benefit; ondansetron, which lacks the same α7 action, did not reproduce it [7]. Human studies consistently show better P50 gating, but a systematic review found the wider sensory-processing literature heterogeneous and too small to establish clinical cognitive benefit [8].

At antiemetic doses the common signal is headache. In the 152-patient dose trial, 5 mg controlled acute nausea and vomiting better than 2 mg but caused more headache [6]. Broader reviews describe tropisetron as generally well tolerated in adults and children receiving chemotherapy [1].

The schizophrenia studies were small. Ten milligrams daily for eight weeks was reported as well tolerated [3], while two participants assigned to 20 mg daily withdrew because of adverse effects in the ten-day dose-ranging trial [4]. The paper's abstract does not specify those effects, so they should not be guessed.

CYP2D6 makes exposure unusually variable. After a 5 mg oral dose, bioavailability ranged from 27% to 99%; slower CYP2D6 metabolism meant higher bioavailability [9]. A fixed dose can therefore produce materially different exposure between people.